A consequence of this disruption resides in the abnormality of neurotransmitter release, related to HPA axis [157]
doi: 10.1016/j.arr.2025.102665, 101 Plascencia-VillaG.PerryG
van Beusekom 4 , Rick Dijkhuizen 5 , Bob Roozenbeek 6,7 , Diederik Dippel 6 , Wim Van Zwam 8,9 , Hugo Ten Cate 10,11,12,13 , Henri Spronk 1,11,12,13 , Robert van Oostenbrugge 1,8 , Magdolna Nagy 11,12,14 1 Cardiovascular Research Institute Maastricht, Maastricht, Netherlands, 2 Department of Neurology, Maastricht Medical Center+, Maastricht, Netherlands, 3 Department of Hematology, Erasmus MC Cardiovascular Institute, University Medical Center Rotterdam, Rotterdam, Netherlands, 4 Division of Experimental Cardiology, Department of Cardiology, Erasmus MC Cardiovascular Institute, University Medical Center Rotterdam, Rotterdam, Netherlands, 5 Translational Neuroimaging Group, Center for Image Sciences, University Medical Center Utrecht and Utrecht University, Utrecht, Netherlands, 6 Department of Neurology, Erasmus MC University Medical Center, Rotterdam, Netherlands, 7 Department of Radiology and Nuclear Medicine, Erasmus MC University Medical Center, Rotterdam, Netherlands, 8 Department of Neurology, Maastricht University Medical Center+, Maastricht, Netherlands, 9 Department of Radiology and Nuclear Medicine, Maastricht University Medical Center+, Maastricht, Netherlands, 10 Cardiovascular Research Institute Maastricht (CARIM), Maastricht University, Maastricht, Netherlands, 11 Department of Biochemistry, Maastricht University, Maastricht, Netherlands, 12 Thrombosis Expertise Center, Heart & Vascular Center, Maastricht University Medical Center+, Maastricht, Netherlands, 13 Department of Internal Medicine, Maastricht University Medical Center+, Maastricht, Netherlands, 14 Cardiovascular Research Institute Maastricht, Department of Biochemistry, Maastricht University, Thrombosis Expertise Center, Heart & Vascular Center, Maastricht University Medical Center+, Maastricht, Netherlands Background and Aims: Administration of periprocedural antithrombotics (unfractionated heparin (UFH), aspirin (ASA), or a combination (UFH+ASA) may reduce thrombotic complications and microvascular occlusions which both might interfere with outcome after endovascular treatment (EVT)
Significant elevation in the GR activity was also reported in HFD-fed mice (de Freitas Carvalho et al
